Gene Therapy On Neurological Diseases Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Gene Therapy On Neurological Diseases Market Between 2025 And 2029?

The gene therapy on neurological diseases market has seen substantial growth recently. It is anticipated to expand from $3.13 billion in 2024 to $3.55 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.2%. This historical growth can be ascribed to several factors, including the increasing occurrence of neurological disorders, a heightened demand for personalized medicine, rising investment in biotech research and development, an increase in clinical trial activities, and more approvals for gene therapies.

The gene therapy on neurological diseases market size is projected to experience swift expansion in the coming years. It is anticipated to reach $5.76 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.9%. The projected growth during this period is attributable to several factors, including heightened global clinical trial activity, advancements in healthcare infrastructure development, greater recognition of rare diseases, an expanding array of gene therapies in development, and a rise in strategic alliances and partnerships. Key trends foreseen for the forecast period encompass the incorporation of technology into remote patient monitoring, breakthroughs in vector manufacturing platforms, automation driven by technology in biomanufacturing processes, the creation of gene therapies specifically for ultra-rare pediatric central nervous system (CNS) disorders, and the assimilation of genomic screening within clinical environments.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

Which Drivers Are Impacting The Gene Therapy On Neurological Diseases Market?

The increasing incidence of neurological disorders is projected to drive the expansion of the gene therapy on neurological diseases market in the foreseeable future. Neurological disorders are medical conditions that impact the brain, spinal cord, and nerves, leading to a spectrum of symptoms including cognitive, motor, and sensory impairments. The rising prevalence of these conditions is connected to the aging population, as advancing age gradually impairs neuronal function, diminishes brain plasticity, and heightens oxidative stress, all contributing to their development and progression. Gene therapy on neurological diseases assists in managing these disorders by targeting their fundamental genetic causes, thereby offering potential long-term or permanent therapeutic solutions. This approach enhances patient outcomes by restoring or modifying gene function, alleviating symptoms, and minimizing the need for repetitive medical interventions, ultimately improving overall quality of life. For example, in July 2024, the National Health Service, a UK-based government agency, reported 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, reflecting an increase of 3,155 cases compared to May 31, 2024. Hence, the growing prevalence of neurological disorders is a significant factor propelling the growth of the gene therapy on neurological diseases market.

How Is The Gene Therapy On Neurological Diseases Market Classified Into Different Segments?

The gene therapy on neurological diseases market covered in this report is segmented

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What Are The Major Trends Driving The Growth Of The Gene Therapy On Neurological Diseases Market?

Key companies operating in the gene therapy on neurological diseases market are concentrating on developing advanced viral delivery systems, such as the adeno-associated virus serotype 2 (AAV2) vector. These systems aim to improve targeted gene delivery, enhance efficacy, mitigate immune reactions, and enable long-lasting treatments. The adeno-associated virus serotype 2 (AAV2) vector itself is a modified, non-pathogenic viral delivery system utilized in gene therapy to transport therapeutic genes into target cells, particularly neurons, for extended expression. For example, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for its gene therapy addressing aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy employs an AAV2 vector to deliver a functional copy of the DDC gene into the putamen, thereby enabling dopamine production and improving motor functions. The treatment involves a one-time, intraputaminal infusion, meticulously designed to offer sustained therapeutic benefits, substantially enhancing motor function and reducing debilitating symptoms without requiring repeated interventions.

Who Are The Core Companies Influencing The Gene Therapy On Neurological Diseases Market Landscape?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

What Are The Key Regional Factors Influencing The Gene Therapy On Neurological Diseases Market Growth?

North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gene Therapy On Neurological Diseases Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2025, By The Business Research Company

Switchboard Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Mobile Computer Market 2025

https://www.thebusinessresearchcompany.com/report/mobile-computer-market

Surfing Boards Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795